Is TRVI or TVTX more undervalued in 2026?

CirclFi compares Trevi Therapeutics, Inc. (TRVI) and Travere Therapeutics, Inc. (TVTX) using 13 institutional-grade valuation models. TRVI has a Quality of Company score of 4.2/10 while TVTX scores 6.3/10.

Which is a better buy — TRVI or TVTX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do TRVI and TVTX valuations compare?

TRVI at $14.45 and TVTX at $47.76 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

TRVI vs TVTX Valuation Comparison 2026 — Intrinsic Value Analysis

TRVI

Biotechnology

Trevi Therapeutics, Inc.

Quality

4.2

out of 10

Value Trap

LOW

Price

$14.45

Last close

Models

7/13

Active

TVTX

Biotechnology

Travere Therapeutics, Inc.

Quality

6.3

out of 10

Value Trap

SAFE

Price

$47.76

Last close

Models

11/13

Active

Model-by-Model Comparison

Model	Type	TRVI Fair Value	TRVI Upside	TVTX Fair Value	TVTX Upside
Bayesian DCF	Intrinsic	$4.39	-69.7%	$12.78	-73.2%
Earnings Power Value	Intrinsic	—	—	$13.84	-68.6%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.40	-97.3%	$0.55	-98.8%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for TRVI vs TVTX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

TRVI vs TVTX — Which Stock Is More Undervalued?

TVTX scores higher with a 6.3/10 quality rating vs TRVI's 4.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Trevi Therapeutics, Inc. (TRVI) and Travere Therapeutics, Inc. (TVTX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

TRVI currently trades at $14.45 with a QOC of 4.2/10, while TVTX trades at $47.76 with a QOC of 6.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).